Definium Therapeutics, Inc. (DFTX) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD (m); Additional Paid in Capital, Common StockUSD $1.74B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $417.00K; Retained Earnings (Accumulated Deficit)USD $-818.76M.
- 2026-03-31: Common Stock, Value, IssuedUSD (m); Additional Paid in Capital, Common StockUSD $937.79M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $824.00K; Retained Earnings (Accumulated Deficit)USD $-659.77M.
- 2025-12-31: Common Stock, Value, IssuedUSD (m); Additional Paid in Capital, Common StockUSD $913.91M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $1.08M; Retained Earnings (Accumulated Deficit)USD $-582.67M.
- 2025-09-30: Common Stock, Value, IssuedUSD (m); Additional Paid in Capital, Common StockUSD $661.83M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $1.00M; Retained Earnings (Accumulated Deficit)USD $-532.24M.
Definium Therapeutics, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $1.74B | $417.00K | $-818.76M | $918.68M | 3 month · $9.64M | (m) |
| 2026-03-31 | (m) | $937.79M | $824.00K | $-659.77M | $278.85M | 3 month · $7.13M | (m) |
| 2025-12-31 | (m) | $913.91M | $1.08M | $-582.67M | $332.33M | 12 month · $20.10M | (m) |
| 2025-09-30 | (m) | $661.83M | $1.00M | $-532.24M | $130.60M | 3 month · $5.82M | (m) |
| 2025-06-30 | (m) | $649.56M | $807.00K | $-464.97M | $185.40M | 3 month · $5.25M | (m) |
| 2025-03-31 | (m) | $644.23M | $802.00K | $-422.23M | $222.81M | 3 month · $3.43M | (m) |
| 2024-12-31 | $0.00 | $639.51M | $819.00K | $-398.88M | $241.45M | 12 month · $16.91M | (m) |
| 2024-09-30 | $0.00 | $625.51M | $821.00K | $-364.14M | $262.19M | 3 month · $3.84M 9 month · $12.96M | (m) |
| 2024-06-30 | $0.00 | $551.67M | $833.00K | $-350.45M | $202.05M | 3 month · $5.43M 6 month · $9.12M | (m) |
| 2024-03-31 | (m) | $539.82M | $836.00K | $-344.60M | $196.06M | 3 month · $3.69M | (m) |
| 2023-12-31 | $0.00 | $367.99M | $343.00K | $-290.20M | $78.13M | 12 month · $15.18M | (m) |
| 2023-09-30 | (m) | $361.54M | $777.00K | $-266.34M | $95.98M | 3 month · $4.20M 9 month · $11.61M | (m) |
| 2023-06-30 | (m) | $354.02M | $362.00K | $-248.41M | $105.97M | 3 month · $3.76M 6 month · $7.41M | (m) |
| 2023-03-31 | (m) | $348.99M | $641.00K | $-219.28M | $130.34M | 3 month · $3.65M | (m) |
| 2022-12-31 | (m) | $344.76M | $627.00K | $-194.47M | $150.92M | 12 month · $13.66M | 12 month · $-407.00K |
| 2022-09-30 | (m) | $342.42M | $743.00K | $-189.56M | $153.59M | 3 month · $4.29M 9 month · $12.27M | 9 month · $-407.00K |
| 2022-06-30 | (m) | $296.73M | $850.00K | $-173.08M | $124.50M | 3 month · $4.17M 6 month · $7.98M | 6 month · $-407.00K |
| 2022-03-31 | (m) | $291.93M | $997.00K | $-156.12M | $136.81M | 3 month · $3.81M | 3 month · $-407.00K |
| 2021-12-31 | (m) | $288.29M | $1.05M | $-137.67M | $151.66M | 12 month · $37.03M | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | $164.27M | 3 month · $4.47M 9 month · $33.31M | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | $171.63M | 3 month · $27.63M 6 month · $28.84M | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | $180.59M | 3 month · $1.21M | (m) |
| 2020-12-31 | (m) | $120.22M | $284.00K | $-44.64M | $75.87M | 12 month · $1.59M | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | $4.78M | (m) | (m) |
| 2019-05-29 | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cronos Group Inc. (CRON) | $1.223B | ||
| Tilray Brands, Inc. (TLRY) | United States | $0.554B | -5.97 |
| Canopy Growth Corp (CGC) | $0.395B | ||
| USANA HEALTH SCIENCES INC (USNA) | United States | $0.264B | -17.90 |
| Niagen Bioscience, Inc. (NAGE) | United States | $0.238B | 15.72 |
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| MANNATECH INC (MTEX) | United States | $0.014B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| Synergy CHC Corp. (SNYR) | United States | $0.001B | |
| Functional Brands Inc. (MEHA) | United States | $0.001B |